Sheela Ranganathan

Sheela Ranganathan is an associate in the Governmental Practice in the firm's Washington, D.C. office and a member of the firm’s Healthcare Team.

Areas of Practice 

Sheela Ranganathan advises healthcare clients on regulatory and antitrust matters. She is also a member of the firm’s Women in Healthcare Leadership Collaborative, whose goal is to promote the advancement of women in the healthcare industry.

Sheela received her J.D. with honors from the University of Texas School of Law, where she served as President of the Asian Pacific American Law Students Association, co-founded the Texas Health Law Society, and was inducted to the Friar Society, the oldest honor society at the University of Texas at Austin. She also served as a Research Editor for the Texas International Law Journal, a Staff Editor for the Texas Journal on Civil Liberties & Civil Rights, and a Dean’s Fellow. Also during law school, Sheela was a research assistant for Professors Elizabeth Sepper, Michelle Deitch, Shavonne Henderson, and Kevin Haynes, and participated in the Supreme Court Clinic and the Capital Punishment Clinic where she assisted with post-conviction appeals and moots for oral arguments. She also interned with the Texas Health and Human Services Commission, the ACLU Disability Rights Program, and Hartford HealthCare. Sheela received her B.S. in Healthcare Management and Policy from Georgetown University’s School of Nursing and Health Studies.

Articles

Healthcare Law Blog

• "CMS Releases CY2024 Final Rule for PACE Organizations," May 2, 2023

• "Supreme Court Hears Arguments on False Claims Act Scienter Standard," April 19, 2023

• "CMS Releases First Set of Part B Rebatable Drugs for Coinsurance Adjustment Under IRA," March 15, 2023
• "PBM Practices Receive Increased Federal Scrutiny," March 15, 2023
• "Tracking the Waivers: Implications of the Wind Down of the COVID-19 Public Health Emergency," March 14, 2023

• "CMS Releases Guidance on Implementation of Rebate Programs for Certain Medicare Part B and Part D Drugs," February 22, 2023

• "Private Equity and Digital Health in 2023: Policy Updates and Trends to Watch," February 1, 2023

• "CMS Issues CY2024 Proposed Rule for Medicare Advantage Organizations and Part D Sponsors," January 5, 2023

• "CMS Proposes to Amend Overpayment Rule, Remove Potential Overpayment and False Claims Act Liability for Mere Negligence," December 27, 2022

• "Private Equity & Healthcare: Antitrust Enforcement in 2023–PE Roll-Ups in the Cross Hairs," December 15, 2022

• "CMS Includes MAOs in Data Exchange and Prior Authorization Requirements," December 15, 2022

• "Pharmaceutical Manufacturers Ask EDVa to Allow Cost-Sharing Under the AKS," November 21, 2022
• "Senate Committee Issues Report On Deceptive Marketing Practices in Medicare Programs," November 4, 2022
• "CMS Heightens Oversight of TPMO Marketing Programs, Restricts TV Advertisements," October 31, 2022
• "2023 Payment Rule’s Nondiscrimination Provisions and Anticipation of New Section 1557 Rules," May 17, 2022
• "Medicaid and Health Equity: CalAIM’s Bold Experiment," May 16, 2022
• "CMS Proposes to Revise, Again, the Stark Law’s Definition of “Indirect Compensation Arrangement”: What Was Old is New Again," July 14, 2021
• "Site-Neutral Payments Stand: SCOTUS Declines to Hear AHA Appeal, Preserving Lower Payments to Off-Campus Provider-Based Departments," July 8, 2021

Events